OS Therapies (OSTX) Competitors $2.15 -0.03 (-1.38%) Closing price 04:00 PM EasternExtended Trading$2.14 -0.01 (-0.28%) As of 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock OSTX vs. VOR, ALMS, IMMP, TKNO, SCPH, ALLO, SGMT, SOPH, AARD, and FENCShould you be buying OS Therapies stock or one of its competitors? The main competitors of OS Therapies include Vor Biopharma (VOR), Alumis (ALMS), Prima BioMed (IMMP), Alpha Teknova (TKNO), scPharmaceuticals (SCPH), Allogene Therapeutics (ALLO), Sagimet Biosciences (SGMT), SOPHiA GENETICS (SOPH), Aardvark Therapeutics (AARD), and Adherex Technologies (FENC). These companies are all part of the "pharmaceutical products" industry. OS Therapies vs. Its Competitors Vor Biopharma Alumis Prima BioMed Alpha Teknova scPharmaceuticals Allogene Therapeutics Sagimet Biosciences SOPHiA GENETICS Aardvark Therapeutics Adherex Technologies OS Therapies (NYSE:OSTX) and Vor Biopharma (NYSE:VOR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends. Do analysts recommend OSTX or VOR? OS Therapies presently has a consensus price target of $18.00, suggesting a potential upside of 737.21%. Vor Biopharma has a consensus price target of $6.07, suggesting a potential upside of 195.93%. Given OS Therapies' stronger consensus rating and higher probable upside, equities research analysts clearly believe OS Therapies is more favorable than Vor Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OS Therapies 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40Vor Biopharma 0 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.56 Does the media prefer OSTX or VOR? In the previous week, Vor Biopharma had 19 more articles in the media than OS Therapies. MarketBeat recorded 23 mentions for Vor Biopharma and 4 mentions for OS Therapies. Vor Biopharma's average media sentiment score of 0.35 beat OS Therapies' score of -0.18 indicating that Vor Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OS Therapies 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Vor Biopharma 5 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger valuation and earnings, OSTX or VOR? OS Therapies is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOS TherapiesN/AN/A-$7.79M-$0.86-2.50Vor BiopharmaN/AN/AN/A-$13.66-0.15 Is OSTX or VOR more profitable? Company Net Margins Return on Equity Return on Assets OS TherapiesN/A N/A -569.57% Vor Biopharma N/A N/A N/A Do insiders & institutionals have more ownership in OSTX or VOR? 97.3% of Vor Biopharma shares are owned by institutional investors. 13.8% of OS Therapies shares are owned by insiders. Comparatively, 2.9% of Vor Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryVor Biopharma beats OS Therapies on 6 of the 11 factors compared between the two stocks. Get OS Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for OSTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OSTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OSTX vs. The Competition Export to ExcelMetricOS TherapiesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$67.99M$806.58M$5.76B$20.88BDividend YieldN/A4.84%3.91%3.59%P/E Ratio-2.501.1530.7828.34Price / SalesN/A25.87456.6454.34Price / CashN/A19.5625.2217.82Price / BookN/A6.609.374.54Net Income-$7.79M-$4.93M$3.26B$992.74M7 Day Performance20.79%0.05%1.88%0.30%1 Month Performance31.10%-0.11%3.73%1.14%1 Year Performance-45.84%21.07%28.93%11.01% OS Therapies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OSTXOS Therapies2.218 of 5 stars$2.15-1.4%$18.00+737.2%-37.4%$67.99MN/A-2.50N/ANews CoverageVORVor Biopharma1.9979 of 5 stars$2.04-4.7%$6.07+197.4%+114.5%$258.43MN/A-1.24140News CoverageAnalyst RevisionALMSAlumis2.9862 of 5 stars$4.85+2.1%$20.17+315.8%-62.1%$258.43MN/A0.00N/ANews CoverageEarnings ReportAnalyst UpgradeAnalyst RevisionIMMPPrima BioMed1.7329 of 5 stars$1.78+2.9%$7.00+293.3%-21.2%$253.94M$5.14M0.002,021TKNOAlpha Teknova1.8605 of 5 stars$4.41-6.0%$10.00+126.8%-10.9%$250.99M$37.74M-10.50240SCPHscPharmaceuticals4.5615 of 5 stars$4.78+3.9%$14.00+192.9%-7.9%$245.17M$36.33M-2.6430Short Interest ↓ALLOAllogene Therapeutics3.0078 of 5 stars$1.09-0.9%$8.44+674.7%-52.4%$244.07M$20K-0.98310Earnings ReportAnalyst RevisionSGMTSagimet Biosciences3.1992 of 5 stars$7.55-1.6%$25.67+240.0%+174.5%$235.28M$2M-4.138Earnings ReportSOPHSOPHiA GENETICS2.9752 of 5 stars$3.49+0.6%$8.00+129.2%+7.1%$234.50M$65.17M-7.93520Short Interest ↓AARDAardvark TherapeuticsN/A$10.44-3.2%$32.80+214.2%N/A$233.89MN/A0.0018News CoverageEarnings ReportAnalyst RevisionFENCAdherex Technologies2.2554 of 5 stars$8.20-1.9%$13.33+62.6%+47.5%$232.52M$47.54M-19.5210News CoverageEarnings ReportAnalyst UpgradeAnalyst Revision Related Companies and Tools Related Companies Vor Biopharma Competitors Alumis Competitors Prima BioMed Competitors Alpha Teknova Competitors scPharmaceuticals Competitors Allogene Therapeutics Competitors Sagimet Biosciences Competitors SOPHiA GENETICS Competitors Aardvark Therapeutics Competitors Adherex Technologies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:OSTX) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OS Therapies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share OS Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access